• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Agrylin (anagrelide)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Agrylin (anagrelide)

  • Profile

Profile

Contact Information

Contact: Takeda
Website: https://www.takeda.com/what-we-do/our-products/www.takeda

Currently Enrolling Trials

    Show More

    General Information

    Agrylin (anagrelide) is a platelet reducing agent.

    Agrylin is specifically indicated for the treatment of thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events.

    Agrylin is supplied as capsules for oral administration. The recommended starting dose for adults is 0.5 mg four times a day or 1 mg twice a day. The starting dose for pediatric patients is 0.5 mg per day. Maintain the starting dose for at least one week and then titrate to maintain target platelet counts.  Do not exceed a dose increment of 0.5 mg/day in any one week. Do not exceed 10 mg/day or 2.5 mg in a single dose. For patients with moderate hepatic impairment, start with 0.5 mg per day.

    Mechanism of Action

    Agrylin (anagrelide) is a platelet reducing agent. The precise mechanism by which anagrelide reduces blood platelet count is unknown. In cell culture studies, anagrelide suppressed expression of transcription factors including GATA-1 and FOG-1 required for megakaryocytopoiesis, ultimately leading to reduced platelet production.

    Side Effects

    Adverse effects associated with the use of Agrylin may include, but are not limited to, the following:

    • headache
    • palpitations
    • diarrhea
    • asthenia
    • edema
    • nausea
    • abdominal pain
    • dizziness
    • pain
    • dyspnea
    • cough,
    • flatulence
    • vomiting
    • fever
    • peripheral edema
    • rash
    • chest pain
    • anorexia
    • tachycardia
    • malaise
    • paresthesia
    • back pain
    • pruritus
    • dyspepsia

    Clinical Trial Results

    The FDA approval of Agrylin in adults was based on three clinical trials in a total of 942 patients with myeloproliferative neoplasms including 551 patients with Essential Thrombocythemia (ET), 117 patients with Polycythemia Vera (PV), 178 patients with Chronic Myelogenous Leukemia (CML), and 96 patients with other myeloproliferative neoplasms (OMPN).  Patients were enrolled in clinical trials if their platelet count was ≥900,000/µL on two occasions or ≥650,000/µL on two occasions with documentation of symptoms associated with thrombocythemia. The mean duration of Agrylin therapy for ET, PV, CML, and OMPN patients was 65, 67, 40, and 44 weeks, respectively; 23% of patients received treatment for 2 years. Patients were treated with Agrylin starting at doses of 0.5-2.0 mg every 6 hours. The dose was increased if the platelet count was still high, but to no more than 12 mg each day. Efficacy was defined as reduction of platelet count to or near physiologic levels (150,000-400,000/µL). The trial demonstrated efficacy by meeting the criteria for “responders”, defined as the reduction in platelets for at least 4 weeks to ≤600,000/µL, or by at least 50% from baseline value.

     

    Approval Date: 1998-12-01
    Company Name: Takeda
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Revamp-360x240.png

      Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

    • AskTheExpertsGreen-360x240.png

      Ask the Experts: Managing Investigational Products

    • SurveywBlueBackground-360x240.png

      Survey Outlines Site Challenges, Successes on Diversity

    • PatientCentricity-360x240.png

      Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing